Non-Hodgkins lymphoma (NHL) is a type of cancer, occurring due to abnormal functioning of leukocytes and B or T lymphocytes. Around 80% of the lymphomas arise in the developing cells and remaining arise in developing T cells. Generally, this occurs, in bone marrow, blood, spleen, lymph nodes, and other organs that are part of lymphatic system. Majority of patients suffering from non-Hodgkin’s lymphoma exhibit common symptoms such as fatigue, fever, weight loss, swelling of lymph nodes, anorexia, and dyspnoea. NHL treatment relies on whether the cells are fast or slow growing and also whether it is spread in one area or different areas of the body. Common treatment options for NHL including monoclonal antibody therapy, radiation therapy, targeted therapy, stem cell transplantation, chemotherapy, and immunotherapy. If blood thickens in the patient due to presence of antibodies then plasmapheresis can also be carried out. Various products available for treating lymphoma include Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex and Decadron.
Request Here For FREE PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/547
Increasing launch of new drugs is expected to drive growth of the global non-Hodgkin’s lymphoma treatment market during the forecast period. For instance, a new drug Axicabtagene ciloleucel, received priority review status to get commercialize for the treatment of non-Hodgkin’s lymphoma as a second line therapy. This drug is expected to launch in later of year 2017.
Some cellular therapies such as T cell therapy and CAR T cell therapy are also being developed where patient’s own T cells are used to attack non-Hodgkin’s lymphoma cells. Also various small molecule targeted therapies such as idelalisib and ibrutinib are latest advancements for the treatment of NHL.
Non-Hodgkins lymphoma treatment market taxonomy:
On the basis of type of non-hodgkins lymphoma, the non-hodgkins lymphoma treatment market is classified into:
On the basis of end user, the non-hodgkins lymphoma treatment market is classified into:
Although Rituxan drug is used to treat NHL and had been a front-line treatment regimen, there has been an increasing rituximab resistance. Therefore, rigorous research and development activities are in place, in order to overcome this resistance. For instance, Roche, Inc. is conducting phase IIIstudy of Gazyva/Gazyvaro in people with previously untreated with diffuse large B-cell lymphoma. The extension of already marketed drugs such as Velcade as a front-line therapy for mantle cell lymphoma (MCL), Revlimid for maintenance therapy of diffuse large B-cell lymphoma (DLBCL) and Adcetris for CD30 T-cell lymphoma would be further contributing towards the non-hodgkins lymphoma treatment market growth. In 2016, the U.S. Government allocated US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training purpose.
Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/547
By geography, North America accounts for the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.
Key players in the non-Hodgkin’s lymphoma treatment market include Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S and AbbVie, Inc.
Key companies are focused on adopting organic and inorganic strategies, in order to gain a competitive edge in the market. For instance, For instance, in 2015, Novartis AG collaborated with Aduro Biotech for clinical trial of novel immuno-oncology product such as ADU-S100 that is expected to treat non-Hodgkin’s lymphoma. Furthermore, taking a step ahead, Roche launched a global network of immunotherapy centers named as Immunotherapy Centers of Research Excellence (imCORE) Network in 2016. This network intends to develop potential therapies for non-Hodgkin’s lymphoma by developing drugs that will simulate one’s immune system to fight the disease.
Reasons to Purchase this Report
• Current and future of global Non-Hodgkins Lymphoma Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞!!!!!!!
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓o 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Purchase This Premium Report With Discounted Rate @ https://www.coherentmarketinsights.com/insight/buy-now/547
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Non-Hodgkins Lymphoma Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Non-Hodgkins Lymphoma Treatment Industry Impact
Chapter 2 Global Non-Hodgkins Lymphoma Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Non-Hodgkins Lymphoma Treatment (Volume and Value) by Type
2.3 Global Non-Hodgkins Lymphoma Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Non-Hodgkins Lymphoma Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 6 East Asia Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 7 Europe Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 8 South Asia Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 9 Southeast Asia Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 10 Middle East Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 11 Africa Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 12 Oceania Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 13 South America Non-Hodgkins Lymphoma Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Non-Hodgkins Lymphoma Treatment Business
Chapter 15 Global Non-Hodgkins Lymphoma Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027